drug
Fluarix
Marketedupdated 6mo agoby GlaxoSmithKline Consumer Healthcare LP
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying Fluarix
- phase1A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children
- phase3Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants
- phase3Immunogenicity Trial of 3 Influenza Vaccines
- phase3A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
- phase4A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India
- phase2A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health
- phase3A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older
- phase2Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.
News(2)
- Osivax focuses on combo strategy for flu vaccine after phase 2 failOsivax has been forced to narrow the strategy for its influenza vaccine after the shot failed a phase 2b study.fiercebiotech · 14d ago
- Osivax bags flu vaccine rights to pursue combination shot visionOsivax has licensed an influenza vaccine from GC Biopharma, positioning the biotech to build on early evidence that its midphase candidate complements traditional flu shots.fiercebiotech · 2mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that